Bosentan as a bridge to pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension

被引:73
作者
Reesink, Herre J. [1 ]
Surie, Sulaiman [1 ]
Kloek, Jaap J. [2 ]
Tan, Hanno L. [3 ]
Tepaske, Robert [4 ]
Fedullo, Peter F. [5 ]
Bresser, Paul [1 ]
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Pulmonol, NL-1100 DE Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Cardiothorac Surg, NL-1100 DE Amsterdam, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Dept Cardiol, NL-1100 DE Amsterdam, Netherlands
[4] Univ Amsterdam, Acad Med Ctr, Dept Intens Care Med, NL-1100 DE Amsterdam, Netherlands
[5] Univ Calif San Diego, Div Repiratory & Crit Care Med, San Diego, CA 92103 USA
关键词
RIGHT-VENTRICULAR DYSFUNCTION; BRAIN NATRIURETIC PEPTIDE; THERAPY; SILDENAFIL; MORTALITY; MARKER;
D O I
10.1016/j.jtcvs.2009.03.053
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: In proximal chronic thromboembolic pulmonary hypertension, pulmonary endarterectomy is the treatment of first choice. In general, medical treatment before pulmonary endarterectomy is not indicated. However, selected "high-risk" patients might benefit by optimization of pulmonary hemodynamics. Moreover, in patients whose surgery is delayed owing to limited medical resources, pretreatment may prevent clinical deterioration. The primary objective of this study was to determine whether the dual endothelin-1 antagonist bosentan improves pulmonary hemodynamics and functional capacity in patients with proximal chronic thromboembolic pulmonary hypertension waiting for pulmonary endarterectomy. Methods: We used an investigator-initiated, randomized, controlled single-blind study. Patients were randomized to receive bosentan (n = 13) or no bosentan (n = 12) for 16 weeks, next to "best standard of care." The primary end point was change in total pulmonary resistance. Secondary end points included changes in 6-minute walk distance, mean pulmonary artery pressure, and cardiac index. Results: After 16 weeks, the mean differences in change from baseline between the groups were as follows: total pulmonary resistance 299 dynes . s . cm(-5) (P = .004), 6-minute walk distance 33 m (P = .014), mean pulmonary artery pressure 11 mm Hg (P = .005), and cardiac index 0.3 L . min(-1) . m(-2) (P = .08). Treatment with bosentan was safe. After pulmonary endarterectomy, 4 patients died (no-bosentan group: n = 3); the short-term in-hospital postoperative clinical course was similar in both groups of patients. Conclusions: Patients with proximal chronic thromboembolic pulmonary hypertension may benefit hemodynamically and clinically from treatment with bosentan before pulmonary endarterectomy. Individual factors predictive of a beneficial response and whether this influences either morbidity or mortality associated with pulmonary endarterectomy remain to be established. (J Thorac Cardiovasc Surg 2010; 139: 85-91)
引用
收藏
页码:85 / 91
页数:7
相关论文
共 34 条
  • [1] CHRONIC MAJOR-VESSEL THROMBOEMBOLIC PULMONARY-ARTERY OBSTRUCTION - APPEARANCE AT ANGIOGRAPHY
    AUGER, WR
    FEDULLO, PF
    MOSER, KM
    BUCHBINDER, M
    PETERSON, KL
    [J]. RADIOLOGY, 1992, 182 (02) : 393 - 398
  • [2] Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension
    Bauer, M
    Wilkens, HC
    Langer, F
    Schneider, SO
    Lausberg, H
    Schäfers, HJ
    [J]. CIRCULATION, 2002, 105 (09) : 1034 - 1036
  • [3] Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism
    Becattini, Cecilia
    Agnelli, Giancarlo
    Pesavento, Raffaele
    Silingardi, Mauro
    Poggio, Renzo
    Taliani, Maria Rita
    Ageno, Walter
    [J]. CHEST, 2006, 130 (01) : 172 - 175
  • [4] Bonderman D, 2005, CHEST, V128, P2599, DOI 10.1378/chest.128.4.2599
  • [5] Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension
    Bresser, P
    Fedullo, PF
    Auger, WR
    Channick, RN
    Robbins, IM
    Kerr, KM
    Jamieson, SW
    Rubin, LJ
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2004, 23 (04) : 595 - 600
  • [6] Bresser Paul, 2006, Proc Am Thorac Soc, V3, P594, DOI 10.1513/pats.200605-115LR
  • [7] Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study
    Channick, RN
    Simonneau, G
    Sitbon, O
    Robbins, IM
    Frost, A
    Tapson, VF
    Badesch, DB
    Roux, S
    Rainisio, M
    Bodin, F
    Rubin, LJ
    [J]. LANCET, 2001, 358 (9288) : 1119 - 1123
  • [8] ATS statement: Guidelines for the six-minute walk test
    Crapo, RO
    Casaburi, R
    Coates, AL
    Enright, PL
    MacIntyre, NR
    McKay, RT
    Johnson, D
    Wanger, JS
    Zeballos, RJ
    Bittner, V
    Mottram, C
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 166 (01) : 111 - 117
  • [9] Chronic thromboembolic pulmonary hypertension
    Dartevelle, P
    Fadel, E
    Mussot, S
    Chapelier, A
    Hervé, P
    de Perrot, M
    Cerrina, J
    Ladurie, FL
    Lehouerou, D
    Humbert, M
    Sitbon, O
    Simonneau, G
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2004, 23 (04) : 637 - 648
  • [10] ETA and ETB receptors modulate the proliferation of human pulmonary artery smooth muscle cells
    Davie, N
    Haleen, SJ
    Upton, PD
    Polak, JM
    Yacoub, MH
    Morrell, NW
    Wharton, J
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 165 (03) : 398 - 405